Download MendeleyGNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).
Crawford, T.D., Audia, J.E., Bellon, S., Burdick, D.J., Bommi-Reddy, A., Cote, A., Cummings, R.T., Duplessis, M., Flynn, E.M., Hewitt, M., Huang, H.R., Jayaram, H., Jiang, Y., Joshi, S., Kiefer, J.R., Murray, J., Nasveschuk, C.G., Neiss, A., Pardo, E., Romero, F.A., Sandy, P., Sims, R.J., Tang, Y., Taylor, A.M., Tsui, V., Wang, J., Wang, S., Wang, Y., Xu, Z., Zawadzke, L., Zhu, X., Albrecht, B.K., Magnuson, S.R., Cochran, A.G.(2017) ACS Med Chem Lett 8: 737-741
- PubMed: 28740608
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00132
- Primary Citation of Related Structures:
5V84 - PubMed Abstract:
The biological function of bromodomains, epigenetic readers of acetylated lysine residues, remains largely unknown. Herein we report our efforts to discover a potent and selective inhibitor of the bromodomain of cat eye syndrome chromosome region candidate 2 (CECR2). Screening of our internal medicinal chemistry collection led to the identification of a pyrrolopyridone chemical lead, and subsequent structure-based drug design led to a potent and selective CECR2 bromodomain inhibitor (GNE-886) suitable for use as an in vitro tool compound.
Organizational Affiliation:
Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States.
